Vice President, FP&A & Financial Transformation

The posting, as insitro wrote it

THE OPPORTUNITY

insitro is looking for a senior finance leader to build and run our FP&A function, and to take what is already an AI-forward finance capability into the next generation of FP&A. We've done the work of embedding AI across finance; this role owns taking that foundation further so the business has seamless access to information and makes faster, better-informed decisions.

Your year-one priorities: move us from a bi-annual budget to a rolling quarterly forecast; make scenario planning routine enough that the Executive Team sees the budget impact of a decision in days, not weeks; extend our AI-enabled, self-serve FP&A capability; and tighten the partnership with Accounting so planning, close, and reporting run as one system.

You'll own the company-wide budget and forecast, the headcount and compensation model, and the financial materials for the Executive Team and Board, and you'll present directly to the Board. You'll partner closely with Research, Platform, Clinical Development, People, and G&A, serve as a standing partner to Accounting leadership, and work tightly with Investor Relations, Corporate Strategic Finance, and Corporate Development to keep the internal plan and the external financial narrative consistent.

Based in South San Francisco, this position reports to the CFO, leads the FP&A team (today, our Director of R&D and Clinical FP&A), and offers an in-person hybrid schedule of three days per week, on average.

RESPONSIBILITIES

Planning, Forecasting & Scenario Analysis

• Own the Planning Cycle: Run the planning calendar end to end, covering the annual operating plan, quarterly reforecasts, and the long-range plan.
• Rolling Forecast: Lead the shift from a bi-annual budget to a rolling quarterly forecast.
• Bottom-Up Budget: Build the annual budget across Research, Platform and Compute, Clinical Development, lab operations, and G&A.
• Scenario Planning: Make scenario planning a standing capability that quantifies the budget impact of decisions before commitments are made.

Next-Generation FP&A & Finance Systems

• Systems Roadmap: Own insitro's finance systems roadmap for planning and analysis, including how Oracle Cloud ERP is configured and used across finance alongside ongoing integration of LLM-based tools and potential onboarding of an FP&A solution.
• Scale AI-Enabled FP&A: Use LLM-based tools directly in your own work and turn strong individual practices into durable, team-wide capability.
• Automate & Integrate: Automate management packages, scorecards, and variance reports, and work with IT and Accounting so Oracle, the data warehouse, and AI tooling form one architecture.
• Self-Serve Access: Give cost center managers and project leads dashboards and data access so they can make decisions without waiting on FP&A.

Business & Accounting Partnership

• R&D, Clinical & Compute Finance: Translate Research, Platform, and clinical plans into cost, headcount, and timeline models, covering tr

[…]
provides transport to and from our South San Francisco HQ from locations all around the Bay Area

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

#LI-Hybrid

Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com http://insitro.com, and if in doubt, contact us at info@insitro.com.

About insitro

insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com http://www.insitro.com.